Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

Description

An open-label, randomized, active control inpatient trial to evaluate the efficacy and tolerability of sublingual dexmedetomidine for the treatment of agitation in inpatients with schizophrenia or bipolar disorder as measured by the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) and Agitation-Calmness Evaluation Scale (ACES). Lorazepam will serve as the active control.

Conditions

Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine

Talk to us

Study Overview

On this page

Study Details

Study overview

An open-label, randomized, active control inpatient trial to evaluate the efficacy and tolerability of sublingual dexmedetomidine for the treatment of agitation in inpatients with schizophrenia or bipolar disorder as measured by the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) and Agitation-Calmness Evaluation Scale (ACES). Lorazepam will serve as the active control.

An Open-Label, Randomized, Active Controlled Inpatient Trial Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

Condition
Schizophrenia Agitation
Intervention / Treatment

-

Contacts and Locations

Philadelphia

Temple University Episcopal Hospital, Philadelphia, Pennsylvania, United States, 19125

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * The participant is an adult between the ages of 18-55 at the time of study participation
  • * Hospitalized on an inpatient unit at Episcopal Hospital
  • * Meet the DSM-5 criteria for schizophrenia, schizoaffective disorder, or bipolar disorder, as determined by routine clinical assessment conducted upon admission.
  • * Are able to understand and read English
  • * Are able to provide informed consent
  • * Experiencing a moderate (PANSS-EC score ≥14 and \<20) or severe (PANSS-EC score ≥20) episode of agitation
  • * Women who are pregnant or breastfeeding
  • * Prisoners
  • * Participant has an allergy to dexmedetomidine or lorazepam
  • * Participant has mild, moderate or severe hepatic impairment
  • * Participant has active pulmonary disease and is receiving treatment (oxygen, inhalers)
  • * Individual is currently prescribed scheduled benzodiazepines or methadone
  • * Participant history of QTc ≥ 500 msec or a history of arrythmia
  • * Participant recent (within the last 2 days) fall, syncope (passing out), feeling lightheaded, or pulse \<50.
  • * Individual has a history of hypokalemia or hypomagnesemia within the past 2 years?
  • * Participant is receiving high-risk medications, including:
  • 1. Methadone
  • 2. Midazolam
  • 3. Opioids
  • 4. High risk medications associated with the QT interval prolongation (sertindole, chlorpromazine, ziprasidone), (amiodarone, iboga, quinine, arsenic, ibutilide, selpercatinib, ivosidenib, bedaquiline, lenvatinib, sotalol, levoketoconazole, cisapride, vendetanib, mobocertinib, disopyramide, papaverine)

Ages Eligible for Study

18 Years to 55 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Temple University,

Study Record Dates

2024-07-01